PriceTargets.com logo

AbCellera Biologics - ABCL Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $7.80
  • Forecasted Upside: 36.24%
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 1 Strong Buy Ratings
$5.73 As of 06/17/2026 01:22 PM ET
▲ +0.635 (12.48%)

This chart shows the closing price for ABCL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AbCellera Biologics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABCL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABCL

Analyst Price Target is $7.80
▲ +36.24% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for AbCellera Biologics in the last 3 months. The average price target is $7.80, with a high forecast of $11.00 and a low forecast of $4.00. The average price target represents a 36.24% upside from the last price of $5.73.

This chart shows the closing price for ABCL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 investment analysts is to moderate buy stock in AbCellera Biologics. This rating has held steady since March 2026, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/22/2025
  • 1 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
12/19/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/19/2026
  • 1 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
5/18/2026
  • 1 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/17/2026

Latest Recommendations

  • 1 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/5/2026Cantor FitzgeraldInitiated CoverageOverweight$7.00
4/20/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
4/10/2026JonesTradingInitiated CoverageBuy$11.00
4/9/2026JonesTradingUpgradeStrong-Buy
1/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/7/2025Leerink PartnersDowngradeStrong-Buy ➝ Hold
11/7/2025Leerink PartnersReiterated RatingOutperform ➝ Market Perform$4.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/8/2025Stifel NicolausLower TargetBuy ➝ Buy$8.00 ➝ $7.00
7/14/2025KeyCorpBoost TargetOverweight ➝ Overweight$5.00 ➝ $10.00
7/7/2025Leerink PartnersUpgradeStrong-Buy
7/7/2025Leerink PartnersInitiated CoverageOutperform$5.00
5/16/2025Truist FinancialLower TargetBuy ➝ Buy$28.00 ➝ $10.00
4/16/2025KeyCorpBoost TargetOverweight ➝ Overweight$4.00 ➝ $5.00
3/3/2025BenchmarkReiterated RatingHold ➝ Hold
2/28/2025Stifel NicolausLower TargetBuy ➝ Buy$12.00 ➝ $10.00
1/8/2025KeyCorpLower TargetOverweight ➝ Overweight$5.00 ➝ $4.00
11/5/2024BenchmarkReiterated RatingHold
11/5/2024Stifel NicolausReiterated RatingBuy ➝ Buy$14.00 ➝ $12.00
8/20/2024BenchmarkDowngradeBuy ➝ Hold
7/11/2024KeyCorpReiterated RatingOverweight ➝ Overweight$7.00 ➝ $5.00
5/8/2024KeyCorpLower TargetOverweight ➝ Overweight$8.00 ➝ $7.00
2/22/2024BenchmarkUpgradeHold ➝ Buy$9.00
2/21/2024Stifel NicolausLower TargetBuy ➝ Buy$21.00 ➝ $17.00
12/5/2023KeyCorpInitiated CoverageOverweight$6.00
11/6/2023BenchmarkDowngradeBuy ➝ Hold
11/3/2023Bloom BurtonReiterated RatingBuy
10/13/2023Piper SandlerReiterated RatingOverweight
8/31/2023BenchmarkLower TargetBuy ➝ Buy$20.00 ➝ $12.00
8/4/2023The Goldman Sachs GroupLower TargetBuy ➝ Buy$27.00 ➝ $24.00
5/5/2023SVB SecuritiesLower Target$16.00 ➝ $15.00
2/28/2023TD CowenInitiated CoverageOutperform
2/22/2023Credit Suisse GroupReiterated RatingOutperform$34.00
2/22/2023BMO Capital MarketsLower TargetOutperform$40.00 ➝ $32.00
1/6/2023Leerink PartnersLower TargetOutperform$20.00 ➝ $18.00
12/15/2022The Goldman Sachs GroupInitiated CoverageBuy$30.00
11/16/2022Truist FinancialInitiated CoverageBuy$29.00
11/9/2022Leerink PartnersBoost TargetOutperform$13.00 ➝ $20.00
11/1/2022Piper SandlerLower Target$22.00 ➝ $21.00
8/10/2022Credit Suisse GroupLower TargetOutperform$40.00 ➝ $34.00
7/26/2022Piper SandlerBoost TargetOverweight$21.00 ➝ $22.00
5/11/2022BMO Capital MarketsReiterated RatingBuy$40.00
5/11/2022Piper SandlerLower Target$28.00 ➝ $21.00
2/25/2022Credit Suisse GroupBoost TargetOutperform$39.00 ➝ $40.00
2/25/2022Leerink PartnersLower TargetOutperform$25.00 ➝ $20.00
2/25/2022Piper SandlerLower Target$33.00 ➝ $28.00
12/21/2021BenchmarkInitiated CoverageBuy$27.00
12/19/2021Bloom BurtonReiterated RatingBuy
11/18/2021Piper SandlerInitiated CoverageOverweight$33.00
8/15/2021Leerink PartnersReiterated RatingBuy
8/13/2021Credit Suisse GroupLower TargetOutperform$51.00 ➝ $49.00
6/28/2021Berenberg BankReiterated RatingBuy
(Data available from 6/17/2021 forward)

News Sentiment Rating

0.42 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/19/2025
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/19/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
1/18/2026
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2026
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2026
  • 3 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/18/2026
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/17/2026

Current Sentiment

  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

AbCellera Biologics logo
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Read More

Today's Range

Now: $5.73
Low: $5.17
High: $5.74

50 Day Range

MA: $4.68
Low: $3.30
High: $6.46

52 Week Range

Now: $5.73
Low: $2.74
High: $6.79

Volume

2,673,276 shs

Average Volume

5,388,452 shs

Market Capitalization

$1.75 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18

Frequently Asked Questions

What sell-side analysts currently cover shares of AbCellera Biologics?

The following Wall Street analysts have issued reports on AbCellera Biologics in the last twelve months: Cantor Fitzgerald, JonesTrading, KeyCorp, Leerink Partners, Stifel Nicolaus, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for ABCL.

What is the current price target for AbCellera Biologics?

0 Wall Street analysts have set twelve-month price targets for AbCellera Biologics in the last year. Their average twelve-month price target is $7.80, suggesting a possible upside of 44.5%. JonesTrading has the highest price target set, predicting ABCL will reach $11.00 in the next twelve months. Leerink Partners has the lowest price target set, forecasting a price of $4.00 for AbCellera Biologics in the next year.
View the latest price targets for ABCL.

What is the current consensus analyst rating for AbCellera Biologics?

AbCellera Biologics currently has 1 sell rating, 1 hold rating, 3 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ABCL.

What other companies compete with AbCellera Biologics?

Other companies that are similar to AbCellera Biologics include PTC Therapeutics, Mirum Pharmaceuticals, Rhythm Pharmaceuticals, Centessa Pharmaceuticals and Cogent Biosciences. Learn More about companies similar to AbCellera Biologics.

How do I contact AbCellera Biologics' investor relations team?

The company's listed phone number is 604-559-9005 and its investor relations email address is [email protected]. The official website for AbCellera Biologics is www.abcellera.com. Learn More about contacing AbCellera Biologics investor relations.